Dengue vaccine: an update

Safety and Immunogenicity of an AS03B-Adjuvanted Inactivated Tetravalent Dengue Virus Vaccine Administered on Varying Schedules to Healthy U.S. Adults: A Phase 1/2 Randomized Study

(2020) Leyi Lin et al.   AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE

Dengue hemorrhagic fever – A systemic literature review of current perspectives on pathogenesis, prevention and control

(2020) Wen-Hung Wang et al.   JOURNAL OF MICROBIOLOGY IMMUNOLOGY AND INFECTION

Safety and immunogenicity of a tetravalent dengue vaccine in children aged 2–17 years: a randomised, placebo-controlled, phase 2 trial

(2020) Vianney Tricou et al.   LANCET

Efficacy of a tetravalent dengue vaccine in healthy children aged 4–16 years: a randomised, placebo-controlled, phase 3 trial

(2020) Shibadas Biswal et al.   LANCET

Safety and immunogenicity of the tetravalent, live-attenuated dengue vaccine Butantan-DV in adults in Brazil: a two-step, double-blind, randomised placebo-controlled phase 2 trial

(2020) Esper G Kallas et al.   LANCET INFECTIOUS DISEASES

Comparison of purified psoralen-inactivated and formalin-inactivated dengue vaccines in mice and nonhuman primates

(2020) Appavu K. Sundaram et al.   VACCINE

Efficacy after 1 and 2 doses of CYD-TDV in dengue endemic areas by dengue serostatus

(2020) Gustavo H. Dayan et al.   VACCINE

Immune Response Persistence and Safety of a Booster Dose of the Tetravalent Dengue Vaccine in Adolescents and Adults Who Previously Completed the 3-dose Schedule 4–5 Years Earlier in Latin America

(2020) Diana Coronel et al.   PEDIATRIC INFECTIOUS DISEASE JOURNAL

Historical discourse on the development of the live attenuated tetravalent dengue vaccine candidate TV003/TV005

(2020) Anna P Durbin   Current Opinion in Virology

Dengue vaccine development by the year 2020: challenges and prospects

(2020) Annelies Wilder-Smith   Current Opinion in Virology

Efficacy of a Dengue Vaccine Candidate (TAK-003) in Healthy Children and Adolescents 2 Years after Vaccination

(2020) Eduardo López-Medina et al.   JOURNAL OF INFECTIOUS DISEASES

Accuracy and efficacy of pre-dengue vaccination screening for previous dengue infection with five commercially available immunoassays: a retrospective analysis of phase 3 efficacy trials

(2020) Carlos A DiazGranados et al.   LANCET INFECTIOUS DISEASES

Evaluation of the oral immunogenicity of M cell-targeted tetravalent EDIII antigen for development of plant-based edible vaccine against dengue infection

(2019) Byeong-Young Kim et al.   PLANT CELL TISSUE AND ORGAN CULTURE

Detection of post-vaccination enhanced dengue virus infection in macaques: An improved model for early assessment of dengue vaccines

(2019) Maria Beatriz Borges et al.   PLoS Pathogens

Persistent Dengue Infection in an Immunosuppressed Patient Reveals the Roles of Humoral and Cellular Immune Responses in Virus Clearance

(2019) Kar-Hui Ng et al.   Cell Host & Microbe

Efficacy of a Tetravalent Dengue Vaccine in Healthy Children and Adolescents

(2019) Shibadas Biswal et al.   NEW ENGLAND JOURNAL OF MEDICINE

Efficient Delivery of Dengue Virus Subunit Vaccines to the Skin by Microprojection Arrays

(2019) David A. Muller et al.   Vaccines

Phase I Randomized Study of a Tetravalent Dengue Purified Inactivated Vaccine in Healthy Adults from Puerto Rico

(2018) Clemente Diaz et al.   AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE

Immunogenicity and safety of one versus two doses of tetravalent dengue vaccine in healthy children aged 2–17 years in Asia and Latin America: 18-month interim data from a phase 2, randomised, placebo-controlled study

(2018) Xavier Sáez-Llorens et al.   LANCET INFECTIOUS DISEASES

Comparative immunogenicity of preparations of yeast-derived dengue oral vaccine candidate

(2018) Jyotiranjan Bal et al.   Microbial Cell Factories

Effect of Dengue Serostatus on Dengue Vaccine Safety and Efficacy

(2018) Saranya Sridhar et al.   NEW ENGLAND JOURNAL OF MEDICINE

Immunogenicity of the CYD tetravalent dengue vaccine using an accelerated schedule: randomised phase II study in US adults

(2018) Judith Kirstein et al.   BMC INFECTIOUS DISEASES

Recent Developments in Recombinant Protein–Based Dengue Vaccines

(2018) Nagesh K. Tripathi et al.   Frontiers in Immunology

Immunogenicity and safety of an investigational tetravalent recombinant subunit vaccine for dengue: results of a Phase I randomized clinical trial in flavivirus-Naïve adults

(2018) Susan B. Manoff et al.   Human Vaccines & Immunotherapeutics

Dengue in the elderly: a review

(2017) Ray Junhao Lin et al.   Expert Review of Anti-Infective Therapy

Analyses of clinical and laboratory characteristics of dengue adults at their hospital presentations based on the World Health Organization clinical-phase framework: Emphasizing risk of severe dengue in the elderly

(2017) Hong-Jie Kuo et al.   JOURNAL OF MICROBIOLOGY IMMUNOLOGY AND INFECTION

Molecular engineering and plant expression of an immunoglobulin heavy chain scaffold for delivery of a dengue vaccine candidate

(2017) Mi-Young Kim et al.   PLANT BIOTECHNOLOGY JOURNAL

Antibody-dependent enhancement of severe dengue disease in humans

(2017) Leah C. Katzelnick et al.   SCIENCE

Elaboration of tetravalent antibody responses against dengue viruses using a subunit vaccine comprised of a single consensus dengue envelope sequence

(2017) Jin Sun et al.   VACCINE

Towards development of a universal dengue vaccine – How close are we?

(2017) Ee Leen Pang et al.   Asian Pacific Journal of Tropical Medicine

Antibodies Against Modified NS1 Wing Domain Peptide Protect Against Dengue Virus Infection

(2017) Yen-Chung Lai et al.   Scientific Reports

The live attenuated dengue vaccine TV003 elicits complete protection against dengue in a human challenge model

(2016) Beth D. Kirkpatrick et al.   Science Translational Medicine

Recombinant lipidated dengue-3 envelope protein domain III stimulates broad immune responses in mice

(2016) Chen-Yi Chiang et al.   VACCINE

Immunogenicity of a novel tetravalent vaccine formulation with four recombinant lipidated dengue envelope protein domain IIIs in mice

(2016) Chen-Yi Chiang et al.   Scientific Reports

Dengue Virus NS1 Disrupts the Endothelial Glycocalyx, Leading to Hyperpermeability

(2016) Henry Puerta-Guardo et al.   PLoS Pathogens

Development of TV003/TV005, a single dose, highly immunogenic live attenuated dengue vaccine; what makes this vaccine different from the Sanofi-Pasteur CYD™ vaccine?

(2015) Stephen S. Whitehead   Expert Review of Vaccines

Robust and Balanced Immune Responses to All 4 Dengue Virus Serotypes Following Administration of a Single Dose of a Live Attenuated Tetravalent Dengue Vaccine to Healthy, Flavivirus-Naive Adults

(2015) Beth D. Kirkpatrick et al.   JOURNAL OF INFECTIOUS DISEASES

Complexity of Neutralizing Antibodies against Multiple Dengue Virus Serotypes after Heterotypic Immunization and Secondary Infection Revealed by In-Depth Analysis of Cross-Reactive Antibodies

(2015) Wen-Yang Tsai et al.   JOURNAL OF VIROLOGY

Efficacy and Long-Term Safety of a Dengue Vaccine in Regions of Endemic Disease

(2015) Sri Rezeki Hadinegoro et al.   NEW ENGLAND JOURNAL OF MEDICINE

Efficacy of a Tetravalent Dengue Vaccine in Children in Latin America

(2015) Luis Villar et al.   NEW ENGLAND JOURNAL OF MEDICINE

Preclinical development of a dengue tetravalent recombinant subunit vaccine: Immunogenicity and protective efficacy in nonhuman primates

(2015) Dhanasekaran Govindarajan et al.   VACCINE

A tetravalent dengue vaccine containing a mix of domain III-P64k and domain III-capsid proteins induces a protective response in mice

(2014) Alienys Izquierdo et al.   ARCHIVES OF VIROLOGY

Clinical efficacy and safety of a novel tetravalent dengue vaccine in healthy children in Asia: a phase 3, randomised, observer-masked, placebo-controlled trial

(2014) Maria Rosario Capeding et al.   LANCET

Evaluation in mice of the immunogenicity and protective efficacy of a tetravalent subunit vaccine candidate against dengue virus

(2014) Laura Lazo et al.   MICROBIOLOGY AND IMMUNOLOGY

Induction of Neutralizing Antibodies against Four Serotypes of Dengue Viruses by MixBiEDIII, a Tetravalent Dengue Vaccine

(2014) Hui Zhao et al.   PLoS One

Recombinant lipidated dengue-4 envelope protein domain III elicits protective immunity

(2014) Chen-Yi Chiang et al.   VACCINE

Current state and recent advances in biopharmaceutical production in Escherichia coli, yeasts and mammalian cells

(2013) Aleš Berlec et al.   JOURNAL OF INDUSTRIAL MICROBIOLOGY & BIOTECHNOLOGY

A Single Dose of Any of Four Different Live Attenuated Tetravalent Dengue Vaccines Is Safe and Immunogenic in Flavivirus-naive Adults: A Randomized, Double-blind Clinical Trial

(2013) Anna P. Durbin et al.   JOURNAL OF INFECTIOUS DISEASES

The global distribution and burden of dengue

(2013) Samir Bhatt et al.   NATURE

Eliciting cross-neutralizing antibodies in mice challenged with a dengue virus envelope domain III expressed in Escherichia coli

(2012) Jie Yang et al.   CANADIAN JOURNAL OF MICROBIOLOGY

Dengue

(2012) Cameron P. Simmons et al.   NEW ENGLAND JOURNAL OF MEDICINE

Refining the Global Spatial Limits of Dengue Virus Transmission by Evidence-Based Consensus

(2012) Oliver J. Brady et al.   PLoS Neglected Tropical Diseases

Efficacy of a Tetravalent Chimeric Dengue Vaccine (DENVax) in Cynomolgus Macaques

(2011) Jorge E. Osorio et al.   AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE

Development of DENVax: A chimeric dengue-2 PDK-53-based tetravalent vaccine for protection against dengue fever

(2011) Jorge E. Osorio et al.   VACCINE

Expression of dengue virus E glycoprotein domain III in non-nicotine transgenic tobacco plants

(2010) Mi-Young Kim et al.   BIOTECHNOLOGY AND BIOPROCESS ENGINEERING

Vaxfectin: a versatile adjuvant for plasmid DNA- and protein-based vaccines

(2010) Sean M Sullivan et al.   Expert Opinion on Drug Delivery

Intrinsic antibody-dependent enhancement of microbial infection in macrophages: disease regulation by immune complexes

(2010) Scott B Halstead et al.   LANCET INFECTIOUS DISEASES

In vivo electroporation enhances the potency of poly-lactide co-glycolide (PLG) plasmid DNA immunization

(2010) Christine M. Barbon et al.   VACCINE

Pediatric measles vaccine expressing a dengue tetravalent antigen elicits neutralizing antibodies against all four dengue viruses

(2010) Samantha Brandler et al.   VACCINE

Evaluation of a prototype dengue-1 DNA vaccine in a Phase 1 clinical trial

(2010) Charmagne G. Beckett et al.   VACCINE

Protection against dengue virus by non-replicating and live attenuated vaccines used together in a prime boost vaccination strategy

(2009) Monika Simmons et al.   VIROLOGY

A Tetravalent Dengue Vaccine Based on a Complex Adenovirus Vector Provides Significant Protection in Rhesus Monkeys against All Four Serotypes of Dengue Virus

(2008) K. Raviprakash et al.   JOURNAL OF VIROLOGY

Immunogenicity of a recombinant envelope domain III protein of dengue virus type-4 with various adjuvants in mice

(2008) J. Pradeep Babu et al.   VACCINE